Cytura Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

Cytura Therapeutics General Information

Description

Developer of small-molecule cancer drugs designed to tackle instabilities in the human genome linked to the spread of cancer. The company's drug will slow down or stop genomic instability and could be applied both as a stand-alone therapy and in combination therapy to overcome resistance or avoid relapse, enabling healthcare providers to improve the lives of patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Kloosterstraat 9
  • Pivot Park, Life sciences campus for pharmaceutical innovation
  • 5349 AB Oss
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Kloosterstraat 9
  • Pivot Park, Life sciences campus for pharmaceutical innovation
  • 5349 AB Oss
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytura Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 30-Jun-2023 Completed Generating Revenue
1. Seed Round 23-Apr-2019 Completed Generating Revenue
To view Cytura Therapeutics’s complete valuation and funding history, request access »

Cytura Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytura Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amsterdam UMC Ventures Holding Venture Capital Minority
CD3 Leuven Venture Capital Minority
KU Leuven Research & Development University Minority
Thuja Capital Management Venture Capital Minority
To view Cytura Therapeutics’s complete investors history, request access »

Cytura Therapeutics FAQs

  • When was Cytura Therapeutics founded?

    Cytura Therapeutics was founded in 2018.

  • Where is Cytura Therapeutics headquartered?

    Cytura Therapeutics is headquartered in Oss, Netherlands.

  • What is the size of Cytura Therapeutics?

    Cytura Therapeutics has 4 total employees.

  • What industry is Cytura Therapeutics in?

    Cytura Therapeutics’s primary industry is Drug Discovery.

  • Is Cytura Therapeutics a private or public company?

    Cytura Therapeutics is a Private company.

  • What is Cytura Therapeutics’s current revenue?

    The current revenue for Cytura Therapeutics is .

  • Who are Cytura Therapeutics’s investors?

    Amsterdam UMC Ventures Holding, CD3 Leuven, KU Leuven Research & Development, and Thuja Capital Management have invested in Cytura Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process